Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).

YaoYao Pollock,Matthew R. Smith,Fred Saad,Simon Chowdhury,Stéphane Oudard,Boris Hadaschik,David Olmos,Paul N. Mainwaring,Ji Youl Lee,Hiroji Uemura,Amitabha Bhaumik,Anil Londhe,Oliver Brendan Rooney,Angela Lopez-Gitlitz,Suneel Mundle,Shinta Cheng,Eric J. Small

Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).

2019

YaoYao Pollock
Matthew R. Smith
Fred Saad
Simon Chowdhury
Stéphane Oudard
Boris Hadaschik
David Olmos
Paul N. Mainwaring
Ji Youl Lee
Hiroji Uemura
Amitabha Bhaumik
Anil Londhe
Oliver Brendan Rooney
Angela Lopez-Gitlitz
Suneel Mundle
Shinta Cheng
Eric J. Small

5025Background: SPARTAN, a phase 3 study of APA vs placebo (PBO) added to ongoing ADT in pts with nmCRPC, demonstrated that APA significantly prolongs metastasis-free survival, time to symptomatic ...

Keywords:

Castration
Prostate cancer
Pathology
Apalutamide
Androgen deprivation therapy
Oncology
Medicine
Internal medicine
castration resistant
Placebo
in patient
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations